JP2024167313A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024167313A5 JP2024167313A5 JP2024146208A JP2024146208A JP2024167313A5 JP 2024167313 A5 JP2024167313 A5 JP 2024167313A5 JP 2024146208 A JP2024146208 A JP 2024146208A JP 2024146208 A JP2024146208 A JP 2024146208A JP 2024167313 A5 JP2024167313 A5 JP 2024167313A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910315634.9 | 2019-04-19 | ||
| CN201910315634 | 2019-04-19 | ||
| JP2021562118A JP2022529703A (ja) | 2019-04-19 | 2020-04-15 | 腫瘍治療薬及びその応用 |
| PCT/CN2020/084991 WO2020211792A1 (zh) | 2019-04-19 | 2020-04-15 | 肿瘤治疗剂及其应用 |
| JP2023129054A JP7547581B2 (ja) | 2019-04-19 | 2023-08-08 | 腫瘍治療薬及びその応用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023129054A Division JP7547581B2 (ja) | 2019-04-19 | 2023-08-08 | 腫瘍治療薬及びその応用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024167313A JP2024167313A (ja) | 2024-12-03 |
| JP2024167313A5 true JP2024167313A5 (cg-RX-API-DMAC7.html) | 2025-04-17 |
| JP7854016B2 JP7854016B2 (ja) | 2026-04-30 |
Family
ID=72837018
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021562118A Pending JP2022529703A (ja) | 2019-04-19 | 2020-04-15 | 腫瘍治療薬及びその応用 |
| JP2023129054A Active JP7547581B2 (ja) | 2019-04-19 | 2023-08-08 | 腫瘍治療薬及びその応用 |
| JP2024146208A Active JP7854016B2 (ja) | 2019-04-19 | 2024-08-28 | 腫瘍治療薬及びその応用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021562118A Pending JP2022529703A (ja) | 2019-04-19 | 2020-04-15 | 腫瘍治療薬及びその応用 |
| JP2023129054A Active JP7547581B2 (ja) | 2019-04-19 | 2023-08-08 | 腫瘍治療薬及びその応用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12655199B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3960766A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2022529703A (cg-RX-API-DMAC7.html) |
| CN (2) | CN119613553A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020211792A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7840511B2 (ja) | 2019-02-01 | 2026-04-06 | 石▲薬▼集▲団▼巨石生物制▲薬▼有限公司 | 抗クローディン18抗体及びそれらの使用の方法 |
| CN114366818B (zh) * | 2020-10-15 | 2025-02-25 | 上海美雅珂生物技术有限责任公司 | 抗体药物偶联物及其应用 |
| WO2022206975A1 (zh) * | 2021-04-02 | 2022-10-06 | 原启生物科技(上海)有限责任公司 | Cldn18.2抗原结合蛋白及其用途 |
| WO2023078386A1 (zh) | 2021-11-05 | 2023-05-11 | 正大天晴药业集团股份有限公司 | 抗cldn18.2抗体及其用途 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| TW202535476A (zh) | 2023-10-27 | 2025-09-16 | 大陸商康諾亞生物醫藥科技(成都)有限公司 | 使用抗密連蛋白18.2 adc之癌症治療 |
| WO2025086268A1 (en) | 2023-10-27 | 2025-05-01 | Keymed Biosciences (Chengdu) Co., Ltd. | Cancer treatment with anti-claudin 18.2 adc |
| AU2023470621A1 (en) | 2023-10-27 | 2026-04-30 | Keymed Biosciences Co., Ltd | Cancer treatment with anti-claudin 18.2 adc |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026125345A1 (en) | 2024-12-09 | 2026-06-18 | Astrazeneca Ab | Biliary tract cancer treatment with anti-claudin 18.2 adc |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7229619B1 (en) | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| IL282953B2 (en) | 2012-11-13 | 2026-02-01 | Tron Translationale Onkologie An Der Johannes Gutenberg Univ Mainz Gemeinnutzige Gmbh | Agents for the treatment of claudin-expressing cancers |
| WO2014127785A1 (en) * | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2018006882A1 (zh) | 2016-07-08 | 2018-01-11 | 科济生物医药(上海)有限公司 | 抗密蛋白18a2的抗体及其应用 |
-
2020
- 2020-04-15 US US17/604,735 patent/US12655199B2/en active Active
- 2020-04-15 EP EP20791781.6A patent/EP3960766A4/en active Pending
- 2020-04-15 WO PCT/CN2020/084991 patent/WO2020211792A1/zh not_active Ceased
- 2020-04-15 CN CN202411010644.9A patent/CN119613553A/zh active Pending
- 2020-04-15 CN CN202080028880.7A patent/CN113748133B/zh active Active
- 2020-04-15 JP JP2021562118A patent/JP2022529703A/ja active Pending
-
2023
- 2023-08-08 JP JP2023129054A patent/JP7547581B2/ja active Active
-
2024
- 2024-08-28 JP JP2024146208A patent/JP7854016B2/ja active Active